Loading…
← CockpitCompetitor Analysis › BAVA.CO Bavarian Nordic A/SOpen in the cockpit ↗

Bavarian Nordic A/SBAVA.COCompetitor analysis, valuation and peers

Denmark · DKK·Health Care›Biotechnology

Makes vaccines, including the smallpox/mpox vaccine and travel vaccines such as rabies and cholera.

Momentum strong 68
Mkt cap
$2.82B
US dollars, full cap
Free float
85%
of shares outstanding
$/day
$6.88M
20-day average traded
Fwd P/E
16.6×
forward earnings
ROIC−WACC
+3.5 pp
WACC 5.0%
Hurdle
-32 pp
Req g minus delivered
Next earnings
113 days
11 Mar 2027
Close · DKKDKK 243.00
1D+0.8%
1W+2.1%
1M+0.4%
3M+16.1%
6M+23.4%
YTD+27.3%
1Y+29.9%
ATR %2.5%
52w lowhigh5.5% off high

What Bavarian Nordic A/S does

Makes vaccines, including the smallpox/mpox vaccine and travel vaccines such as rabies and cholera.

A big share comes from government orders for the smallpox and mpox vaccine, awarded as contracts that deliver in lumps; travel vaccines sold to clinics are steadier. Its travel vaccines were bought from other pharma firms, GSK and Emergent, rather than developed in-house.

Products and services

  • Smallpox/mpox vaccine (Jynneos/Imvanex)
  • Rabies vaccine
  • Travel vaccines (cholera, TBE)
  • RSV/other vaccine pipeline

Customers

  • Government stockpile programs (US BARDA, European
  • Travel clinics/public health bodies

Where it sits in the supply chain

  • Biopharmaceuticals
  • Vaccine manufacturing
  • Government/travel vaccine supplier

What could go right

  • Government pandemic-preparedness stockpiling
  • Mpox outbreak-driven demand

What could go wrong

  • Lumpy government order timing/revenue volatility
  • Manufacturing/supply chain execution risk

Moat: narrow (regulatory licence, IP / patents). One of few approved mpox/smallpox vaccine makers with long-term government stockpile contracts.

Headquarters: Hellerup, Denmark · Founded: 1994 · Employees: 1,795

Named competitors

Bavarian Nordic A/S at a glance

Size Bavarian Nordic A/S (BAVA.CO) is a Denmark Health Care company (Biotechnology) with a market value of $2.82B, the 29th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 243.00 on 18 Nov 2026.

Performance Over six months the shares gained 23.4%, against -3.3% for the median peer and +6.3% for the Denmark market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue fell 8.2% over the last twelve months (peer median +12.3%); the operating margin is 18.3% (peer median -2.6%).

Valuation It trades at 16.6× forward earnings against a peer median of 30.6× (2nd cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -32 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.5 points above its cost of capital (5.0% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026BAVA.CO 126Peer median 96
Six months, rebased to 100: Bavarian Nordic A/S against the median of its 20 peers (local-currency closes).

Bavarian Nordic A/S financials

Reported figures in DKK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueDKK 6.30BDKK 6.17BDKK 5.71BDKK 7.06BDKK 3.15B
Revenue growth—+8%-19%+124%—
Gross profitDKK 3.15BDKK 2.92BDKK 2.73BDKK 4.52BDKK 1.65B
EBITDADKK 1.89BDKK 1.64BDKK 1.56BDKK 2.05BDKK 328M
Net incomeDKK 897MDKK 1.38BDKK 988MDKK 1.48B-DKK 347M
Free cash flowDKK 847MDKK 2.52BDKK 1.87BDKK 977M-DKK 141M
Capital expenditureDKK 340MDKK 1.36BDKK 1.69BDKK 977MDKK 1.38B
Total debtDKK 123MDKK 131MDKK 128MDKK 145MDKK 1.19B

Quarterly statements and history in the cockpit →

Bavarian Nordic A/S competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%968822286887RUBICONDNLI028300TLXMBXADMAXNCRXERS688278VIRP300142ELVN300255IOVABAVA.CO6-month return →1-month return →
Up and to the right = strong over both horizons. Bavarian Nordic A/S is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×100×200×300×RUBICONTLXADMAXERS688278VIRP002007300142BAVA.CORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bavarian Nordic A/S is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%75%ADMAXERS688278VIRP002007300142BAVA.COGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bavarian Nordic A/S is the large dot.

Bavarian Nordic A/S competitors and peer comparison

Head to head with its named competitors (BAVA.CO vs EBS vs SAN.PA vs GSK.L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bavarian Nordic A/S BAVA.CO$2.82B+23%-8%18%16.6×-4.3%
Emergent BioSolutions EBSn/a-33%n/an/an/an/a
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%
Valneva VLA.PA$508M-6%-27%-87%n/an/a

How Bavarian Nordic A/S compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bavarian Nordic A/S against its 20 peers (data as of 18 Nov 2026)
MeasureBAVA.COPeer medianRank in peer set
1-month return+0.4%-5.8%7th highest of 21
6-month return+23.4%-3.3%7th highest of 21
Distance from 52-week high-5.5%-31.6%2nd highest of 21
Revenue growth (TTM)-8.2%+12.3%4th lowest of 17
Operating margin18.3%-2.6%4th highest of 18
Forward P/E16.6×30.6×2nd cheapest of 9
Growth the price implies (Req g, 7 yrs)-4.3%10.8%least demanding of 7
Growth delivered (Del g)+27.4%+22.7%4th highest of 7
Hurdle (Req g minus delivered)-31.7 pp-20.1 pp4th least demanding of 7
ROIC minus cost of capital+3.5 pp-9.4 pp4th highest of 18
EV / EBITDA8.7×53.7×cheapest of 6
Net debt / EBITDA-1.5×1.1×least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%16.6×-4.3%+27.4%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%n/an/an/a
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%n/an/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%n/an/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%66.6×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%n/an/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%n/an/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Xencor XNCRUnited States$2.58B+204%+34%-73%n/an/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%15.0×-0.6%+36.0%
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%348.7×29.5%-3.8%
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%n/an/an/a
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a

Questions

Who are Bavarian Nordic A/S's main competitors?
Named competitors: Emergent BioSolutions (EBS), Sanofi (SAN.PA), GSK (GSK.L), Valneva (VLA.PA). The cockpit's measured peer set (industry) also includes Zai Lab (9688.HK), XtalPi (2228.HK), Sunshine Lake Pharma (6887.HK), Rubicon Research (RUBICON.NS), Denali Therapeutics (DNLI), HLB (028300.KS).
Is Bavarian Nordic A/S expensive compared with its peers?
On forward p/e it trades at 16.6× against a peer median of 30.6×, 2nd cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is -32 pp: the price already allows for a slowdown.
How has Bavarian Nordic A/S stock performed?
Over six months to 18 Nov 2026 the shares returned +23.4% against -3.3% for the median peer; over one year +29.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.